Regenetech , Preclinical Studies at Johns Hopkins University with Expanded Adult Stem Cells for Type 1 Diabetes Treatment

14 November 2007 - Regenetech, Inc. announces that it has signed a Sponsored Research Agreement (SRA) with Johns Hopkins University in order to work toward a treatment for type 1 diabetes. This is in addition to the research agreements which the Company currently has in place with Texas A&M University and the University of Texas Medical Branch at Galveston. Regenetech is pioneering the development and commercialization of technology which the company believes will enable regenerative therapy with adult stem cells for widespread use... Regenetech's Press Release -

Cardium, Phase 2b Excellarate Clinical Study for Diabetic Ulcers

Nov. 14, 2007--Cardium Therapeutics (AMEX:CXM) and its subsidiary, Tissue Repair Company (TRC) announced the start of recruitment for its Phase 2b clinical trial (MATRIX) to evaluate the safety and efficacy of Excellarate(TM) for the potential treatment of non-healing diabetic foot ulcers. Excellarate is a DNA-based topical gel that is being developed to be administered once or twice to stimulate wound healing... Cardium's Press Release -

DexCom, FDA Approval to Calibrate Its SEVEN Continuous Glucose Monitoring System Using Any FDA Cleared Blood Glucose Meter

November 16, 2007 - DexCom, Inc. (NASDAQ: DXCM) announced that it has received Food and Drug Administration (FDA) approval to calibrate the SEVEN^TM, its seven-day continuous glucose monitoring system, using any FDA cleared blood glucose meter. With this approval, patients will be able to calibrate the system without using a connection cable. DexCom expects to launch this feature to new patients near the end of the first quarter of 2008 and upgrade existing patients during the second quarter of 2008... DexCom's Press Release -

DIAMYD, A TYPE 1 DIABETES TRIAL WITH THE EXPERIMENTAL DIAMYD DIABETES VACCINE

November 22, 2007 - Diamyd Medical announced that it has executed a Clinical Trial Agreement with the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) for a planned clinical study with the Diamyd® GAD-alum diabetes vaccine in 126 new onset type 1 diabetes patients. The clinical study will be conducted by the NIDDK-sponsored consortium Type 1 Diabetes TrialNet. Under the terms of the agreement, Diamyd Medical will supply clinical-grade material (i.e. Diamyd® and placebo) for the trial... Diamyd's Press Release -

JDRF and Lilly, Research to Identify Beta Cell Biomarkers

Nov 14, 2007 - The Juvenile Diabetes Research Foundation and Eli Lilly and Company announced today that they are joining together to create a $3 million research effort to accelerate the pace of research into drugs and therapies to cure diabetes and its complications by developing biomarkers -- indicators that can measure the progress of disease and the effectiveness of therapeutics... Lilly's Press Release -

Osiris Therapeutics, Phase II Clinical Trial Evaluating Prochymal(TM) for Type 1 Diabetes

Oct 25, 2007 - "Prochymal has shown promise in Phase II clinical trials as a therapy for severe immune mediated conditions including Crohn's Disease and GVHD, and as a result has advanced into Phase III pivotal trials," said C. Randal Mills, Ph.D., President and CEO of Osiris Therapeutics. "It is appropriate to evaluate related conditions such as type 1 diabetes, where data indicates Prochymal may also be of therapeutic benefit. We are honored that JDRF has selected Prochymal as a promising new therapy for evaluation."... Osiris Therapeutics' Press Release -

CV Therapeutics' Anti-Ischemic Agent Ranexa(R), Reduces HbA1c and Other Markers of Diabetes in MERLIN TIMI-36

Nov. 6, 2007- CV Therapeutics, Inc. (Nasdaq: CVTX) announced today that data from a prospectively identified analysis of 2,220 diabetic patients from the MERLIN TIMI-36 study showed that Ranexa(R) (ranolazine extended-release tablets) significantly reduced hemoglobin A1c (HbA1c), increased the number of patients achieving the clinical HbA1c treatment target of 7.0 percent or less and reduced the incidence of newly increased HbA1c in patients without diabetes at baseline... CV Therapeutics' Press Release -

Sangamo BioSciences, ZFP Therapeutic Data From Nerve Regeneration Program

Nov 07, 2007 -...We believe that these effects will prove therapeutically important in conditions that involve nerve damage including diabetic neuropathy, ALS, stroke and traumatic injuries to the brain, spinal cord and other nerves. We are very pleased to collaborate with Dr. Michael Fehlings, senior author of this study, who is world-renown for his work on SCI and has significant clinical trial experience in this area."... Sangamo 's Press Release -

Sirtris, Novel Endogenous SIRT1 Activator

Nov. 9, 2007--... The natural SIRT1 activator, AROS, and Sirtris' proprietary SIRT1 activators both bind to the N-terminus of SIRT1. This further validates SRT501, and more potent Sirtris new chemical entities that are up to 1000 times more potent than SRT501, as potential drug targets for diseases of aging including metabolic disorders such as Type 2 Diabetes, mitochondrial disorders such as MELAS, neurological disorders, and cancer.... Sirtris Press Release -

Forbes Medi-Tech, Final Steps in Compound Selection for Type 2 Diabetes

Tue Oct 30, 2007 - Forbes Medi-Tech Inc. (TSX:FMI and NASDAQ:FMTI) announced that it has entered the final stages of compound selection for two of the most rapidly growing therapeutic indications, asthma and type 2 diabetes... Forbes Medi-Tech's Press Release -

Nanomix, Exclusive Glucose Detection Licensing Agreement with MysticMD

November 5, 2007 - Nanomix Inc., a leading electronic detection company commercializing high-value diagnostic and monitoring applications, today announced an exclusive licensing agreement with MysticMD Inc., a provider of proprietary nano-coatings. Per this agreement, MysticMD will provide Nanomix with intellectual property related to the use of nano-ink for glucose test strip technology... Nanomix's Press Release [PDF] -